A Prospective, Open Label, multi Center clinical Study to evaluate the Safety, Efficacy And Tolerability Of AZADVIR (Herbal Steaminhaler) In Asymptomatic, Mildly Symptomatic COVID -19 Patients And Health Care Workers Posted To Covid Wards

HAOMA WELLNESS CENTER0 sites40 target enrollmentTBD

Overview

No summary available.

Registry

who.int

Start Date

TBD

End Date

January 21, 2021

Last Updated

4 years ago

Study Type

Interventional

Sponsor

HAOMA WELLNESS CENTER

•1\.Male or non\-pregnant female adult with or without comorbidities between the agre group of 18\-85 years of age at time of enrollment
•2\.Has laboratory\-confirmed positive COVID\-19 infection as determined by RT\-PCR or other commercial or public health assay in any specimen, an RT\-PCR (Nasopharynx, Throat, and Blood) test shall be repeated to assess eligibility
•3\.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures
•4\.Health care workers who visited to COVID patients

•1\.Testing positive for HIV, HbsAg, HCV infection, VDRL.
•2\.Females who are currently pregnant or breastfeeding.
•3\.Allergy or other contraindication to one of the investigational products.
•4\.Has received Eflornithine within the last 10 days.
•5\.Has received anti\-viral, anti\-malarial or anti\-bacterial within the last 14 days.
•6\.Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 X upper limit of normal (ULN).
•7\.QTc interval \>\= 500ms.
•8\.Recent Myocardial Infarction (within last 6 months).
•9\.Known case of (K/C/O) Congestive heart failure.
•10\.K/C/O Chronic Kidney Disease.